Journal Home
Search for

Volume 195, Issue 1, Pages 1-11 (November 2009)


View previous. 3 of 19 View next.

Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC–DUX4 fusion gene event

Maisa Yoshimotoa, Cassandra Grahambc, Susan Chilton-MacNeillb, Eric Leeb, Mary Shagobc, Jeremy Squirea, Maria Zielenskabc, Gino R. SomersbcCorresponding Author Informationemail address

Received 1 June 2009; accepted 17 June 2009.

Refers to erratum:
Erratum
Cancer Genetics and Cytogenetics
February 2010 (Vol. 197, Issue 1, Page 99)
Full Text | Full-Text PDF (43 KB)

Abstract 

Pediatric undifferentiated soft tissue sarcomas (USTS) are a diagnostically challenging group of neoplasms. Recently, a subcategory of USTS with primitive round cell morphology and a t(4;19)(q35;q13) rearrangement has been defined. The present study applied high-throughput array comparative genomic hybridization together with spectral karyotyping, four-color fluorescence in situ hybridization (FISH), and reverse transcriptase–polymerase chain reaction (RT-PCR) to a series of three pediatric USTS. Two of these had primitive round cell morphology with CD99 positivity; the third had a spindled and myxoid appearance. By genomic analyses, both primitive round cell sarcomas had t(4;19)(q13;q35) rearrangements in addition to several imbalances throughout the genome. Four-color FISH and in silico analyses of the breakpoint region at 19q13 identified the potential involvement of the candidate oncogene CIC. By RT-PCR, fusion transcripts involving CIC (19q13) and DUX4 (4q35) were confirmed to be present in both primitive round cell sarcomas, further defining the breakpoints seen by genomic analysis. Described here are two tumors belonging to the rare category of CIC–DUX4-positive primitive sarcomas, with detailed cytogenetic and genomic information regarding this novel subclass of pediatric malignancy. Molecular and cytogenetic techniques for the detection of the CIC–DUX4 fusion gene are described, to aid in recognition and diagnosis.

a Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada

b Department of Paediatric Laboratory Medicine, Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G 1X8, Canada

c Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

Corresponding Author InformationCorresponding author. Tel.: (416) 813-6848; fax: (416) 813-5974.

PII: S0165-4608(09)00328-8

doi:10.1016/j.cancergencyto.2009.06.015


View previous. 3 of 19 View next.